Linked Life Data

2904685

Source:http://linkedlifedata.com/resource/pubmed/id/2904685

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1989-1-26
pubmed:abstractText
Flumazenil (Flu) (Ro 15-1788, Anexate) is a newly synthetized specific benzodiazepine (BZD) antagonist which was recently introduced for clinical study. The drug was intravenously injected, in titrated doses, to patients undergoing diagnostic or therapeutic procedures in order to reverse the sedative effects of BZDs. A total of 63 patients undergoing hand surgery under i.v. regional block, lower abdominal surgery under epidural anesthesia, cardiac catheterization, intracardiac catheter ablation, cardioversion, gastroscopy and bronchoscopy were studied. Flu in a dose ranging from 0.1 to 0.42 mg effectively reversed BZD-induced sedation in all patients 1-2 min following i.v. injection. Patients were fully awake and oriented yet calm and in good mood. Flu was well tolerated even in the high risk cardiac patients, with no significant changes in vital signs nor any sign of local irritation at the site of Flu injection. No significant resedation was observed. Thus Flu was very useful in reversing BZD-induced sedation or unconsciousness in a variety of clinical situations.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0300-9572
pubmed:author
pubmed:issnType
Print
pubmed:volume
16 Suppl
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S49-56
pubmed:dateRevised
2009-8-25
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Early clinical experience in reversing benzodiazepine sedation with flumazenil after short procedures.
pubmed:affiliation
Department of Anesthesia and Intensive Care, Tel Aviv Medical Center, Ichilov Hospital, Israel.
pubmed:publicationType
Journal Article